Boson Ventures

What Boson Ventures does

Boson Ventures is an Australian boutique early-stage venture capital firm founded in 2021 and headquartered in Sydney, with a planned relocation to Melbourne supported by a LaunchVic grant. The firm invests from Pre-seed through Series A/B via its Boson Newton Fund, with a stated thesis concentrated on deep tech across healthcare/biotech, advanced manufacturing, and cleantech, and an 80% deep tech allocation planned for the upcoming Fund II Newton. Its core proposition is cross-border: positioning itself as a regulated bridge between Australian deep tech startups and China's Greater Bay Area ecosystem, formalized through the NSW–GBA Innovation Channel (a bilateral platform co-developed with HKUST Fok Ying Tung Research Institute and Sparks Passion Ventures, launching in 2026) and supplemented by China market entry and due diligence services for third-party investors.

The firm's product surface spans capital deployment (Boson Newton Fund), a pre-accelerator program (Boson Collider), the NSW–GBA cross-border platform, and paid advisory services covering China market entry and competitive diligence. Distribution is hybrid: direct deal sourcing via network and an online application funnel ([email protected]), supplemented by institutional partnerships with ACBC, Baker McKenzie, Cicada Innovations, WEHI, CSL/Jumar Bioincubator, and government backers (LaunchVic, Victorian Government). Revenue is generated through traditional VC fund management economics—management fees on committed capital plus carried interest from portfolio realizations—augmented by service fees and government grants for ecosystem-building activities. The firm operates under ESVCLP tax-advantaged fund rules through its subsidiary Boson Health Tech VC Pty Ltd, which is a corporate authorised representative of Sagestone Asset Management (AFSL 700034).

Name

Boson Ventures

Legal name

Boson Ventures Pty Ltd

Website

https://boson.vc

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Boson Ventures is an Australian boutique early-stage VC firm investing from Pre-seed to Series A/B in deep tech (healthcare, advanced manufacturing, cleantech), with a differentiated cross-border platform connecting Australian startups to China's Greater Bay Area.

Ownership category

akta.pro rank

Product category

Venture Capital

NAICS

Other Investment Pools and Funds (5259)

SIC

Investment Advice (6282)

akta.pro primary industry

Early-Stage Venture Capital (Series A/B) (FSANAAAB)

Keywords

• Venture capital funding
• Deep tech investment
• Startup acceleration programs
• Cross-border commercialization
• Early-stage equity investment

Headquarters

HQ city

Sydney

HQ country

Australia

HQ region

Oceania

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Venture Capital Fund Management: Traditional VC fund structure with management fees and carried interest from portfolio returns. Boson Newton Fund invests from Pre-seed through Series A/B in deep tech companies.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Boson Ventures is an Australian early-stage venture capital firm that invests in deep tech startups from Pre-seed through Series A/B via its Boson Newton Fund, with a focus on healthcare/biotech, advanced manufacturing, and cleantech. Beyond capital deployment, the firm runs the Boson Collider accelerator program and provides cross-border China market entry, supply chain, and due diligence services to portfolio companies and investors. Its strategic position as an Australia-China bridge is reinforced by the NSW-GBA Innovation Channel, a bilateral platform for capital, market access, and talent exchange.

Product overview

Boson Ventures operates as a deep tech and healthcare venture capital firm providing investment services and cross-border market support. The firm offers venture funding (Pre-seed to A/B rounds) through its Boson Fund II Newton, operates the Boson Collider pre-accelerator program, provides China market entry and due diligence services, and has established the NSW–GBA Innovation Channel as a bilateral platform for capital, market access, and talent exchange between Australia and China's Greater Bay Area. The investment thesis focuses on healthcare, advanced manufacturing, and cleantech sectors.

Differentiator

Problem solved

Functional benefit

Brands

• Boson Collider: A program offered by Boson Ventures for startup support and investment opportunities.
• Boson Newton Fund

Products and services

• Boson Newton Fund
• Boson Collider
• China Market Entry Services
• China Market & Technology Due Diligence
• NSW–GBA Innovation Channel

Quantifiable outcome

• DPI 0.2362x, outperforming 90% of global peers
• +1 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Eleven partnerships are on record, tiered core and supporting.

• Sparks Passion VenturescoreStrategic or Co-development Partner · 3 December 2025Co-signed MOU with Boson Ventures and HKUST Fok Ying Tung Research Institute to establish the NSW-GBA Innovation Channel, connecting NSW technology companies with Greater Bay Area ecosystem. The Channel will operate through complementary hubs in Guangzhou and Sydney, launching in 2026.
• Guangzhou HKUST Fok Ying Tung Research Institute (FYTRI)coreStrategic or Co-development Partner · 3 December 2025Partner in establishing the NSW-GBA Innovation Channel. Located at HKUST(GZ) Innovation & Technology Transfer Base in Nansha, provides localization support, supply chain integration, and financing matchmaking for Australian post-Series A companies entering Chinese market.
• Australia China Business Council (ACBC)coreGTM or Marketing PartnerCo-hosted the Australia-China Bioinnovation Roundtable bringing together biotech industry, academia, and policy experts. ACBC CEO Tom Parker leads national operations. Partnership for cross-border innovation dialogue and collaboration facilitation.
• Baker McKenziesupportingImplementation/ SI/ Consulting PartnerHost partner for Cleantech Innovation Roundtable, providing legal and regulatory expertise for cross-border collaboration discussions between Australian and Chinese industry leaders.
• Cicada InnovationssupportingStrategic or Co-development PartnerBoson Ventures Managing Partner Alan Cui mentored on Cicada Innovations' Medtech Commercialisation program which has Customer Discovery sessions. Collaboration on deep tech startup commercialization.
• WEHI (Walter and Eliza Hall Institute)supportingStrategic or Co-development PartnerHosted SJTU Australia Biopharma Delegation. Business development head Dr. Victoria Jameson presented commercialization strategies. Discussed high-throughput screening, automated robotics in drug discovery, and digital pathology innovations.
• University of MelbournesupportingStrategic or Co-development PartnerMet with engineering, medicine, and digital health leaders. Discussed Melbourne Biomedical Precinct capabilities, biomedical engineering solutions, and digital health in pre-clinical research.
• CSL and Jumar BioincubatorsupportingStrategic or Co-development PartnerHosted SJTU delegation. CSL Global Head of Research Innovation Dr. Marthe D'Ombrain presented innovation strategy and R&D pipeline. Jumar showcased portfolio companies including Tessara Therapeutics, Arovella Therapeutics, Misti, Turquoise Biotechnology.
• Peter MacCallum Cancer CentresupportingStrategic or Co-development PartnerGlobal leading cancer research center hosting delegation. Discussed research infrastructure and clinical trial capabilities with Chief Medical Officer Dr. Dishan Herath and commercial leadership.
• CMAX Clinical ResearchsupportingStrategic or Co-development PartnerAustralia's longest-running early clinical trial center visited by delegation. Specializes in first-in-human clinical trials.
• Viva BiotechsupportingStrategic or Co-development PartnerSupporting organization for Australia-China Bioinnovation Roundtable, contributing to cross-border biotech collaboration dialogue.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Blackbird Ventures: One of Australia's largest early-stage VC firms, investing across consumer, enterprise, and deep tech. Comparable as a leading Australian early-stage VC, but with significantly larger fund size, broader stage range, and without Boson's China cross-border specialization.
• Khosla Ventures: US-based, high-conviction early-stage VC with strong deep tech franchise. Comparable in early-stage deep tech investing across healthcare, climate, and advanced tech, but operates at much larger scale and primarily in US markets rather than APAC.
• AirTree Ventures: Major Australian early-stage VC investing from seed to growth across sectors. Comparable in stage focus (Series A/B) and Australian domicile, but operates a much larger fund and broader sector mandate versus Boson's deep tech + China bridge thesis.

Direct peers

• Antler: Global early-stage VC with strong APAC presence and pre-seed/Series A focus across sectors. Comparable in early-stage (pre-seed to Series A), accelerator-style program (similar to Boson Collider), and APAC presence, though with broader sector mandate.
• SOSV: Global early-stage VC specializing in deep tech (biotech, climate, manufacturing) with multiple accelerator programs. Direct peer in deep tech early-stage focus and accelerator-style program approach (similar to Boson Collider), though operates globally at much larger scale.
• Tenacious Ventures: Australia-NZ focused early-stage VC dedicated to agritech and climate tech. Comparable as a regional, sector-focused deep tech VC, though concentrated on agrifood/climate rather than Boson's broader deep tech mandate.
• Main Sequence Ventures: Australia's leading deep tech and science-backed early-stage VC, originally backed by CSIRO. Direct peer in deep tech focus and early-stage investing, with similar sector overlap in healthcare, advanced manufacturing, and cleantech, though with larger fund size and stronger research institution ties.

Emerging players

• SGInnovate: Singapore-based investor focused on deep tech startups (biotech, medtech, advanced manufacturing). Comparable in deep tech, early-stage, and Asia-Pacific focus, with similar government backing model, though domiciled in Singapore rather than Australia.
• Cicada Innovations: Australia's leading deep tech incubator, with explicit focus on medtech, biotech, and advanced materials commercialization. Direct adjacency through its Medtech Commercialisation Program (where Boson's Alan Cui mentors) and overlap in deep tech sector mandate.
• Artesian: Australian alternative asset manager with early-stage VC and venture debt offerings. Comparable in early-stage Australian VC and government-linked programs, though with broader capital stack offerings.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/boson-ventures
• Xx.com/bosonventures

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments11 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Boson Ventures